RHEACELL is a German biopharmaceutical company dedicated to developing innovative drugs, based on the platform technology around the ABCB5 gene family, especially on ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) and has exclusive access to proprietary IP and know how. For its clinical trials, RHEACELL uses ABCB5+ MSCs produced by TICEBA, a company that is specialized in high-throughput, off-the-shelf GMP-manufactured ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs). RHEACELL’s development program is supported by the Müller Holding and TICEBA, a specialist in stem cell manufacturing.